Oncologist-approved cancer information from the American Society of Clinical Oncology

Colorectal Cancer

Cetuximab Works Better than Bevacizumab as Initial Treatment for Advanced Colorectal Cancer

ASCO Annual Meeting
June 1, 2013

According to a recent study, initial treatment with the drug cetuximab (Erbitux) plus the chemotherapy regimen FOLFIRI lengthens the lives of patients with metastatic colorectal cancer when compared with bevacizumab (Avastin) plus FOLFIRI. The chemotherapy regimen FOLFIRI includes the drugs leucovorin (Wellcovorin), fluorouracil (5-FU, Adrucil), and irinotecan (Camptosar).  

Cetuximab Added to Chemotherapy Helps Some Patients With Advanced Colorectal Cancer That Has Spread to the Liver Live Longer

JCO Research Round Up
April 8, 2013

New findings from a clinical trial in patients with colorectal cancer and inoperable metastases in the liver (cancer that has spread from the colon or rectum to the liver) suggest that combination treatment with standard therapy and targeted drug cetuximab (Erbitux) caused significant shrinkage of metastases, making successful surgery feasible. Patients who received cetuximab in addition to traditional chemotherapy lived markedly longer than those who received only chemotherapy. 

Pages

© 2005-2014 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.

Connect With Us: